You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR NSCLC with progression on ≤2 lines of oral TKIs

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

EGFR, NSCLC, Third-generation TKI Trial (Almonertinib and metronomic oral vinorelbine)

Not yet recruiting
  • EGFR
  • +2 more
  • Almonertinib and metronomic oral vinorelbine
  • (no location specified)
Dec 21, 2022

NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

Not yet recruiting
  • NSCLC
  • Oral S-1 + Oral Osimertinib
  • Singapore, Singapore
    National Cancer Center Singapore
Mar 6, 2023

NSCLC Trial in Seoul (BBT-176, Cetuximab)

Recruiting
  • NSCLC
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • +3 more
Jan 6, 2023

Lung Cancer Trial (Lazertinib 240 mg)

Approved for marketing
  • Lung Cancer
  • Lazertinib 240 mg
  • (no location specified)
Feb 15, 2022

NSCLC Trial (TAS3351 oral administration)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • TAS3351 oral administration
  • (no location specified)
Mar 8, 2023

Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

Recruiting
  • Nsclc
  • +5 more
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 25, 2021

NSCLC Stage IV, EGFR T790M Trial in Shanghai (3rd generation EGFR-TKI, Consolidative SBRT)

Recruiting
  • NSCLC Stage IV
  • EGFR T790M
  • 3rd generation EGFR-TKI
  • Consolidative SBRT
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2021

Non Small Cell Lung Cancer Trial in Worldwide (Amivantamab, Lazertinib, Zirabev)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Angers, France
  • +30 more
Oct 31, 2022

NSCLC Trial in Goyang-si (BIBW 2992, simvastatin)

Completed
  • Non-small Cell Lung Cancer
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

NSCLC (NSCLC) Trial in China (Capmatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Xiamen, Fujian, China
  • +18 more
Jan 27, 2023

Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)

Active, not recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Dublin, Ireland
  • +24 more
Aug 23, 2022

EGFR Mutant Advanced Non Small Cell Lung Cancer Trial in Australia, Taiwan (Tremelimumab, Durvalumab)

Recruiting
  • EGFR Mutant Advanced Non Small Cell Lung Cancer
  • Bankstown, New South Wales, Australia
  • +17 more
Sep 28, 2021

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +3 more
  • New Haven, Connecticut
  • +4 more
Jan 27, 2023

Lung Cancer Stage IV Trial (Osimertinib Oral Tablet)

Not yet recruiting
  • Lung Cancer Stage IV
  • Osimertinib Oral Tablet
  • (no location specified)
Aug 17, 2020

Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,

Recruiting
  • Lung Cancer, Non-small Cell
  • +4 more
  • Genomic profiles detection
  • circulating tumor DNA detection
  • Changsha, Hunan, China
    Department of Oncology, The Second Xiangya Hospital, Central Sou
Oct 25, 2022

Advanced Solid Tumors, EGFR Positive NSCLC, Colorectal Carcinoma Trial in United States (TP-0903)

Active, not recruiting
  • Advanced Solid Tumors
  • +4 more
  • Phoenix, Arizona
  • +15 more
Apr 4, 2022

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation Trial in Shanghai (Almonertinib, Pemetrexed, Carboplatin)

Unknown status
  • Lung Cancer, Non-small Cell
  • +2 more
  • Shanghai, Shanghai, China
    Cancer hospital Fudan University
Oct 15, 2020

Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

Not yet recruiting
  • Lung Cancer
  • +4 more
  • (no location specified)
Sep 15, 2023

EGFR Mutant Advanced NSCLC Trial (JIN-A02)

Not yet recruiting
  • EGFR Mutant Advanced Non-small Cell Lung Cancer
  • (no location specified)
Jul 8, 2022

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

NSCLC Trial in China (BBP-398, osimertinib)

Recruiting
  • NSCLC
  • Beijing, Beijing, China
  • +4 more
Sep 4, 2023

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Trial in Worldwide (Atezolizumab, Bevacizumab, Carboplatin)

Active, not recruiting
  • EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
  • Großhansdorf, Germany
  • +17 more
Jan 12, 2023

NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • MK-2870
  • +2 more
  • (no location specified)
Oct 3, 2023

Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)

Recruiting
  • Brain Metastases
  • Non-small Cell Lung Cancer
  • EGFR-TK Inhibitor
  • Stereotactic radiotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 27, 2023